Market share is often held up as the most relevant metric for the success of a biosimilar class. I believe there are other metrics, like cost savings or signs of greater patient access, that should also be used to define biosimilars’ successes or failures.
In the U.S., the first biosimilar was launched in September 2015. As I write this, there are 38 FDA-approved biosimilars; 22 of them are commercially available. These 22 products compete in nine molecule classes across oncology, rheumatology, diabetes care, and now ophthalmology. According to the most recent “U.S. Generic & Biosimilar Medicines Savings Report” from the Association for Accessible Medicines, biosimilar savings in the U.S. were $7.9 billion in 2020 (three times higher than savings from 2019) and have the potential to increase to $133 billion by 2025.
Create a display name to comment
This name will appear with your comment